Stem cell treatment for ischemia, heart failure raises enough for clinical trials MedCity News The regenerative medicine company Juventas Therapeutics, which had already said it added Takeda Pharmaceuticals to its roster of investors, said this weekend it has raised enough money to take its treatments for heart failure and a severe form of ... Juventas Therapeutics Raises $22.2 Million Series B Financing |
